

IMPLANT CHARGES

| A. <u>PRIMARY TOTAL KNEE REPLACEMENT</u> | | |
|--|---|-----------------|
| | | Maxx Gold |
| i | | S & N Oxinium |
| 1 | FEMORAL COMPONENT | 42,613 |
| 2 | Tibial Component Titanium | 26,707 |
| 3 | Articulating Surface | 10,504 |
| 4 | Patella | 4,498 |
| | | <u>84,322</u> |
| | GST @ 5% | 4,216 |
| | Grand Total Rs ... | <u>88,538</u> |
| <hr/> | | |
| | | S & N Legion |
| ii | | |
| 1 | FEMORAL COMPONENT | 25,860 |
| 2 | Tibial Component Titanium | 24,280 |
| 3 | Articulating Surface | 9,550 |
| 4 | Patella | 4,295 |
| | | <u>63,985</u> |
| | GST @ 5% | 3,199 |
| | Grand Total Rs ... | <u>67,184</u> |
| <hr/> | | |
| | | Maxx Freedom |
| iii | | |
| 1 | FEMORAL COMPONENT | 28,445 |
| 2 | Tibial Component Co-Cr | 18,688 |
| 3 | Articulating Surface | 10,504 |
| 4 | Patella | 4,498 |
| | | <u>62,137</u> |
| | GST @ 5% | 3,106 |
| | Grand Total Rs... | <u>65,244</u> |
| <hr/> | | |
| B. <u>UNICONDYLAR KNEE REPLACEMENT (Zimmer-Biomet)</u> | | |
| | | Rs. |
| 1 | FEMORAL COMPONENT | 25860 |
| 2 | Tibial Component Cobalt Chromium | 16990 |
| 3 | Articulating Surface | 9550 |
| | | <u>52400</u> |
| | GST @ 5% | 2620 |
| | Grand Total Rs... | <u>55020</u> |
| <hr/> | | |
| C. <u>REVISION KNEE REPLACEMENT</u> | | |
| | | Rs. |
| i | LEGION Femur | 69,046 |
| | PCK Tibia | 34,341 |
| | Articulating Surface | 17,456 |
| | Patella | 4,498 |
| | | <u>1,25,341</u> |
| | GST @ 5% | 6,267 |
| | Grand Total Rs... | <u>1,31,608</u> |
| <hr/> | | |
| ii | RHK (ROTATING HINGE KNEE - Zimmer Biomet) | Rs. |
| | Femur | 62770 |
| | Tibia | 31220 |
| | Articulating Surface | 15870 |
| | | <u>109860</u> |
| | GST @ 5% | 5493 |
| | Grand Total | <u>115353</u> |
| | | Rs... |

(To be published in Part-II, Section-3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 13th August 2019

ORDER

In continuation to the notifications issued by National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 2668(E) dated 16th August 2017 and S.O. 3987(E) dated 13th August 2018 regarding fixation of ceiling price of the orthopaedic Knee Implants issued under Para 19 of the DPCO, 2013, it has been decided that the same may be monitored as per the provisions of Paragraph 20(1) of the DPCO, 2013. This order shall be applicable for the period of one year from 16th August, 2019 (i.e. up to 15th August, 2020), unless revised by another notification.

2. The ceiling prices for orthopaedic Knee Implants will be reviewed after a period of one year.
3. The notes (b) to (t) of the Notification S.O. 2668(E) dated 16th August, 2017 shall remain in force during the currency of this order.

PN/201/69/2019/F

F. No. 8(69)/2019/DP/NPPA/Div.II

(Prakash Hemani)
Asstt. Director

THE DRUGS (PRICES CONTROL) ORDER, 2013

(Notified by SO 1221 (E) dated 15.05.2013 and as amended
up to vide SO 1192(E) dated 22-03-2016)

In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955, (10 of 1955), and supersession of the Drug (Prices Control) Order, 1995, except as respect to things done or omitted to be done before such supersession, the Central Government hereby makes the following Order, namely:-

1. Short title and commencement.- (1) This Order may be called the Drugs (Prices Control) Order, 2013.

(2) It shall come into force on the date of its publication in the Official Gazette.

2. Definitions.- (1) In this Order, unless the context otherwise requires,-

(a) "**Act**" means the Essential Commodity Act, 1955 (10 of 1955);

(b) "**active pharmaceutical ingredients or bulk drug**" means any pharmaceutical, chemical, biological or plant product including its salts, esters, isomers, analogues and derivatives, conforming to standards specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and which is used as such or as an ingredient in any formulation;

(c) "**brand**" means a name, term, design, symbol, trademark or any other feature that identifies one seller's drug as distinct from those of other sellers;

(d) "**ceiling price**" means a price fixed by the Government for Scheduled formulations in accordance with the provisions of this Order;

(e) "**dealer**" means a person carrying on the business of purchase or sale of drugs, whether as a wholesaler or retailer and includes his agent;

(f) "**distributor**" means a person engaged in the work of distribution of drugs and includes an agent or a stockist for stocking drugs for sale to a dealer;

(g) "**existing manufacturer**" means manufacturer existing on the date of publication of this order in the Official Gazette.

(h) "**Form**" means a form specified in the Second Schedule;

(i) "**formulation**" means a medicine processed out of or containing one or more drugs with or without use of any pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease and, but shall not include -

(i) any medicine included in any bonafide Ayurvedic (including Sidha) or Unani (Tibb) systems of medicines;

18. Revision of ceiling price on the basis of moving annual turnover (MAT).- The revision of ceiling prices on the basis of moving annual turnover value shall be carried out,-

(i) as and when the National List of Essential Medicines is revised by the Ministry of Health and Family Welfare or five years from the date of fixing the ceiling price under this Order whichever is earlier;

(ii) when the number of manufacturers of a scheduled formulation, having price of a scheduled formulation more than or equal to seventy five percent of the ceiling price fixed and notified by the Government, has decreased by twenty five percent or more than the number of manufacturers as existing on the reference date;

(iii) when the number of manufacturers of a scheduled formulation, having prices of their scheduled formulation equal to or lower than twenty five percent of the ceiling price fixed by the Government, has increased by twenty five percent or more than the number of manufacturers as existing on the reference date.

Explanation.- For the purpose of items (ii) and (iii) the "reference date" shall be for first revision of ceiling price May, 2012 and for second or subsequent revision the date of previous revision of the ceiling price.

19. Fixation of ceiling price of a drug under certain circumstances.- Notwithstanding anything contained in this order, the Government may, in case of extra-ordinary circumstances, if it considers necessary so to do in public interest, fix the ceiling price or retail price of any Drug for such period, as it may deem fit and where the ceiling price or retail price of the drug is already fixed and notified, the Government may allow an increase or decrease in the ceiling price or the retail price, as the case may be, irrespective of annual wholesale price index for that year.

20. Monitoring the prices of non-scheduled formulations.- (1) The Government shall monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months and where the increase is beyond ten percent of maximum retail price, it shall reduce the same to the level of ten percent of maximum retail price for next twelve months.

(2) The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of increase in price in addition to the penalty.

21. Monitoring the availability of scheduled formulations.- (1) The Government shall monitor the production and availability of scheduled formulations and the active pharmaceutical ingredients